ABI
MDCO

Adamant Biomedical Investments’s Medicines Co MDCO Stock Holding History

Adamant Biomedical Investments’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$1.38M Hold
50,000
– – 0.33% 76
2014
Q3 		$1.12M Buy
+50,000
New +$1.27M 0.28% 76

Other funds holding MDCO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Adamant Biomedical Investments's MDCO Position: Q4 2014 in Review

Adamant Biomedical Investments held its Medicines Co (MDCO) position steady in Q4 2014 at 50,000 shares worth $1.38M. The position accounts for 0.33% of the portfolio, ranked #76.

Adamant Biomedical Investments first reported a position in MDCO in Q3 2014 and has held it in 2 quarters since. 166 funds tracked by Wall St. Rank hold MDCO as of Q4 2014.

  • Adamant Biomedical Investments held 50,000 shares of Medicines Co worth $1.38M as of Q4 2014.
  • Adamant Biomedical Investments left its Medicines Co share count unchanged in Q4 2014.
  • Medicines Co made up 0.33% of Adamant Biomedical Investments's portfolio in Q4 2014, its #76 holding.
  • Adamant Biomedical Investments first reported a position in Medicines Co in Q3 2014 and has held it in 2 quarters since.
  • 166 funds tracked by Wall St. Rank held Medicines Co as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.